Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant

Bibliography

• Chaudhuri KR, Healy DG, Schapira AH, et al. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-45
   PubMed Web of Science ®Google Scholar
• Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 2003;991:1-14
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998;339:1130-43
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044-53
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-39
   PubMed Web of Science ®Google Scholar
• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56:S1-S88
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. CNS Drugs 2010;24:941-68
   PubMed Web of Science ®Google Scholar
• Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson's disease: what's next? Curr Neurol Neurosci Rep 2012;12:376-85
   PubMed Web of Science ®Google Scholar
• Jenner P, Mori A, Hauser R, et al. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 2009;15:406-13
   PubMed Web of Science ®Google Scholar
• Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 2003;61:S32-8
   PubMedGoogle Scholar
• Fredholm BB, Chern Y, Franco R, et al. Aspects of the general biology of adenosine A2A signaling. Prog Neurobiol 2007;83:263-76
   PubMed Web of Science ®Google Scholar
• Dunwiddie TV, Diao L, Proctor WR. Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. J Neurosci 1997;17:7673-82
   PubMed Web of Science ®Google Scholar
• Zimmermann H. ATP and acetylcholine, equal brethren. Neurochem Int 2008;52:634-48
   Google Scholar
• Fredholm BB, IJzerman AP, Jacobson KA, et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52
   PubMed Web of Science ®Google Scholar
• Fredholm BB, Irenius E, Kull B, et al. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 2001;61:443-8
   PubMed Web of Science ®Google Scholar
• Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther 2005;105:267-310
   PubMed Web of Science ®Google Scholar
• Arslan G, Kull B, Fredholm BB. Signaling via A2A adenosine receptor in four PC12 cell clones. Naunyn Schmiedebergs Arch Pharmacol 1999;359:28-32
   Google Scholar
• Johansson B, Halldner L, Dunwiddie TV, et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 2001;98:9407-12
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Le Moine C, Fisone G, et al. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999;59:355-96
   PubMed Web of Science ®Google Scholar
• Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 2005;67:1385-7
   PubMed Web of Science ®Google Scholar
• Berne RM. The role of adenosine in the regulation of coronary blood flow. Circ Res 1980;47:807-13
   PubMed Web of Science ®Google Scholar
• Bours MJ, Swennen EL, Di Virgilio F, et al. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006;112:358-404
   PubMed Web of Science ®Google Scholar
• Augood SJ, Emson PC. Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. Brain Res Mol Brain Res 1994;22:204-10
   PubMedGoogle Scholar
• Svenningsson P, Le Moine C, Aubert I, et al. Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J Comp Neurol 1998;399:229-40
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Doder M, Osman S, et al. Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. Synapse 2008;62:671-81
   PubMed Web of Science ®Google Scholar
• Obeso JA, Marin C, Rodriguez-Oroz C, et al. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol 2008;64(Suppl 2):S30-46
   PubMedGoogle Scholar
• Kurokawa M, Koga K, Kase H, et al. Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo. J Neurochem 1996;66:1882-8
   PubMed Web of Science ®Google Scholar
• Ciruela F, Casado V, Rodrigues RJ, et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 2006;26:2080-7
   PubMed Web of Science ®Google Scholar
• Quiroz C, Lujan R, Uchigashima M, et al. Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal 2009;9:1321-44
   Google Scholar
• Hettinger BD, Lee A, Linden J, et al. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 2001;431:331-46
   PubMed Web of Science ®Google Scholar
• Ferre S, Quiroz C, Woods AS, et al. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des 2008;14:1468-74
   PubMed Web of Science ®Google Scholar
• Azdad K, Gall D, Woods AS, et al. Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 2009;34:972-86
   PubMed Web of Science ®Google Scholar
• Kull B, Ferre S, Arslan G, et al. Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochem Pharmacol 1999;58:1035-45
   PubMed Web of Science ®Google Scholar
• Halldner L, Lozza G, Lindstrom K, et al. Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur J Pharmacol 2000;406:345-54
   PubMed Web of Science ®Google Scholar
• Ochi M, Koga K, Kurokawa M, et al. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 2000;100:53-62
   PubMed Web of Science ®Google Scholar
• Gasparini F, Di Paolo T, Gomez-Mancilla B. Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinsons Dis 2013;2013:196028
   Google Scholar
• Morin N, Morissette M, Gregoire L, et al. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology 2013;73:216-31
   PubMed Web of Science ®Google Scholar
• Nishi A, Liu F, Matsuyama S, et al. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc Natl Acad Sci USA 2003;100:1322-7
   PubMed Web of Science ®Google Scholar
• Morelli M, Carta AR, Jenner P. Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol 2009;193:589-615
   PubMedGoogle Scholar
• Golembiowska K, Dziubina A. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 2004;47:414-26
   Web of Science ®Google Scholar
• Pinna A, di Chiara G, Wardas J, et al. Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 1996;8:1176-81
   PubMed Web of Science ®Google Scholar
• Calon F, Dridi M, Hornykiewicz O, et al. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004;127:1075-84
   PubMed Web of Science ®Google Scholar
• Xu K, Xu YH, Chen JF, et al. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience 2010;167:475-81
   PubMed Web of Science ®Google Scholar
• Prediger RD. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis 2010;20(Suppl 1):S205-20
   PubMed Web of Science ®Google Scholar
• Bove J, Serrats J, Mengod G, et al. Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. Exp Brain Res 2005;165:362-74
   Google Scholar
• Weiss SM, Benwell K, Cliffe IA, et al. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology 2003;61:S101-6
   PubMedGoogle Scholar
• Chase TN, Bibbiani F, Bara-Jimenez W, et al. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 2003;61:S107-11
   PubMedGoogle Scholar
• Park A, Stacy M. Istradefylline for the treatment of Parkinson's disease. Expert Opin Pharmacother 2012;13:111-14
   PubMed Web of Science ®Google Scholar
• Vallano A, Fernandez-Duenas V, Pedros C, et al. An update on adenosine A2A receptors as drug target in Parkinson's disease. CNS Neurol Disord Drug Targets 2011;10:659-69
   Google Scholar
• Dungo R, Deeks ED. Istradefylline: first global approval. Drugs 2013;73:875-82
   PubMed Web of Science ®Google Scholar
• Aoyama S, Koga K, Mori A, et al. Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain. Brain Res 2002;953:119-25
   PubMed Web of Science ®Google Scholar
• Saki M, Yamada K, Koshimura E, et al. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol 2013;386:963-72
   PubMed Web of Science ®Google Scholar
• Shiozaki S, Ichikawa S, Nakamura J, et al. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 1999;147:90-5
   PubMed Web of Science ®Google Scholar
• Koga K, Kurokawa M, Ochi M, et al. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 2000;408:249-55
   PubMed Web of Science ®Google Scholar
• Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-13
   PubMed Web of Science ®Google Scholar
• Kanda T, Tashiro T, Kuwana Y, et al. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 1998;9:2857-60
   PubMed Web of Science ®Google Scholar
• Betz AJ, Vontell R, Valenta J, et al. Effects of the adenosine A 2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. Neuroscience 2009;163:97-108
   Google Scholar
• Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 2003;184:285-94
   PubMed Web of Science ®Google Scholar
• Carvalho AL, Duarte CB, Carvalho AP. Regulation of AMPA receptors by phosphorylation. Neurochem Res 2000;25:1245-55
   Google Scholar
• Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000;23:S86-91
   PubMed Web of Science ®Google Scholar
• Jones N, Bleickardt C, Mullins D, et al. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. Brain Res Bull 2013;98:163-9
   PubMed Web of Science ®Google Scholar
• Fredduzzi S, Moratalla R, Monopoli A, et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 2002;22:1054-62
   PubMed Web of Science ®Google Scholar
• Muller T. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations. Expert Opin Drug Metab Toxicol 2013;9:1015-24
   PubMed Web of Science ®Google Scholar
• Knebel W, Rao N, Uchimura T, et al. Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. J Clin Pharmacol 2011;51:40-52
   PubMed Web of Science ®Google Scholar
• Knebel W, Rao N, Uchimura T, et al. Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease. J Clin Pharmacol 2012;52:1468-81
   PubMed Web of Science ®Google Scholar
• Rao N, Dvorchik B, Sussman N, et al. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin. J Clin Pharmacol 2008;48:1092-8
   PubMed Web of Science ®Google Scholar
• Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-6
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Greeley DR, Zweig RM, et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 2010;16:16-20
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hubble JP, Truong DD, et al. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63:295-302
   PubMed Web of Science ®Google Scholar
• Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008;70:2233-40
   PubMed Web of Science ®Google Scholar
• Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008;23:2177-85
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 2010;25:1437-43
   PubMed Web of Science ®Google Scholar
• Pourcher E, Fernandez HH, Stacy M, et al. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord 2012;18:178-84
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kondo T. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord 2013;28:1138-41
   PubMed Web of Science ®Google Scholar
• Chen W, Wang H, Wei H, et al. Istradefylline, an adenosine A(2)A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis. J Neurol Sci 2013;324:21-8
   PubMed Web of Science ®Google Scholar
• Factor S, Mark MH, Watts R, et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat Disord 2010;16:423-6
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kirin Initiates a Global Phase 3 Trial of Istradefylline (KW-6002) for Parkinson's Disease. Kyowa Hakko; 2013. Available from: http://www.kyowa-kirin.com/news_releases/2013/e20131121_01.html [Last accessed 6 March 2014]
   Google Scholar
• Bleickardt CJ, Lashomb AL, Merkel CE, et al. Adenosine A(2A) receptor antagonists do not disrupt rodent prepulse inhibition: an improved side effect profile in the treatment of Parkinson's disease. Parkinsons Dis 2012;2012:591094
   PubMed Web of Science ®Google Scholar
• Swerdlow NR, Lelham SA, Sutherland Owens AN, et al. Pramipexole effects on startle gating in rats and normal men. Psychopharmacology (Berl) 2009;205:689-98
   Google Scholar
• Swerdlow NR, Taaid N, Oostwegel JL, et al. Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats. Behav Pharmacol 1998;9:389-96
   Google Scholar
• Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Rev Neurosci 2013;24:267-78
   PubMed Web of Science ®Google Scholar
• Kadowaki Horita T, Kobayashi M, Mori A, et al. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology (Berl) 2013;230:345-52
   PubMed Web of Science ®Google Scholar
• Yamada K, Kobayashi M, Mori A, et al. Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacol Biochem Behav 2013;114-115:23-30
   PubMed Web of Science ®Google Scholar
• Salamone JD, Correa M, Farrar A, et al. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl) 2007;191:461-82
   PubMed Web of Science ®Google Scholar
• Nunes EJ, Randall PA, Santerre JL, et al. Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism. Neuroscience 2010;170:268-80
   Google Scholar
• Black KJ, Koller JM, Campbell MC, et al. Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci 2010;30:16284-92
   PubMed Web of Science ®Google Scholar
• Hauser R, Olanow CW, Kieburtz K, et al. A phase 2, placebo-controlled, randomized, double-blind trial of tozadenant (SYN-115) in patients with Parkinson's disease with wearing-off fluctuations on levodopa. Mov Disord 2013;28(Suppl S1):444
   Google Scholar
• Tozadenant (SYN115): A highly differentiated product for Parkinson's disease Biotie Therapies. 2013. Available from: http://www.biotie.com/en/product_and_development/development_pipeline/syn115 [Last accessed 6 March 2014]
   Google Scholar
• Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79:651-8
   PubMed Web of Science ®Google Scholar